Related Experiment Video
Updated: Aug 14, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
[Antithrombotics in pre-hospital phase of acute coronary syndromes]
J P Collet1, R Dumaine, P Ecollan
1Départment de Cardiogie, Institut de Cardiologie, Bureau. jean-philippe.collet@psl.ap-hop-paris.fr
Insights
Prehospital initiation of antithrombotic therapies, including anticoagulation and GP IIb/IIIa inhibitors, is crucial for managing ST-elevation myocardial infarction (STEMI). Early administration of these treatments offers time-dependent benefits, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Acute coronary syndrome (ACS) management relies heavily on antithrombotic therapies.
- Prehospital care is increasingly recognized as a critical window for initiating these time-sensitive treatments.
Purpose:
- To review the evidence supporting the prehospital initiation of antithrombotic therapies in ACS, particularly STEMI.
- To evaluate the time-dependent benefits of anticoagulation, GP IIb/IIIa inhibitors, and clopidogrel.
Summary:
- Anticoagulation therapy is validated as an effective, time-dependent treatment for STEMI.
- GP IIb/IIIa receptor inhibitors are the preferred adjuvant therapy for primary PCI, reducing mortality.
- Clopidogrel's efficacy is dose- and time-dependent, but prehospital benefit requires further establishment.
Impact:
- Highlights the importance of early intervention in ACS for improved mortality.
- Supports the integration of specific antithrombotic therapies into prehospital STEMI protocols.
- Identifies areas for future research regarding prehospital clopidogrel administration.
Abstract:
Antithrombotic therapies are the corner stone of acute coronary syndrome management. We have the proof that many of them should be initiated during the prehospital care because their clinical benefit is time-dependent. The hypothesis that anticoagulation therapy is an effective treatment of STEMI, which benefit is time-dependent, is now validated. It is also fair to affirm that GP lIb/IIIa receptor inhibitors are the adjuvant therapy of choice for primary PCI. Indeed, these medications reduce short-term and long-term mortality. This clinical benefit is time dependent. Clopidogrel therapy is probably also a medication of the prehospital phase. It is well established now that the biological efficacy of this pro drug is loading dose dependent. It is also demonstrated that its clinical efficacy depends on the time delay between symptom onset and initiation of the therapy. However, the clinical benefit of prehospital administration remains to be established.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management
